insights_auto
Why is FARN down 4.86%?
Dive Deeperchevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 34.25
arrow_downward
-4.86%(-1.75) 1D
Oct 16, 4:41:49 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
GBX 34.10
High
GBX 38.00
Low
GBX 34.00
Mkt. cap
69.44M
Avg. vol.
39.66K
Volume
49.10K
52-wk high
GBX 105.98
52-wk low
GBX 22.21
EPS
-GBX 0.10
Shares outstanding
31.03M
No. of employees
36
Open
GBX 34.10
High
GBX 38.00
Low
GBX 34.00
Mkt. cap
69.44M
Avg. vol.
39.66K
Volume
49.10K
52-wk high
GBX 105.98
52-wk low
GBX 22.21
EPS
-GBX 0.10
Shares outstanding
31.03M
No. of employees
36
News stories
From web sources and news partners
ad-hoc-news.de
·
24 minutes ago
Shentel schedules October 28 results for Shenandoah Telecommunications stock
Simply Wall Street
·
31 minutes ago
FormFactor Is Up 150%, But The Story Isn't Finished
Yahoo Finance
·
44 minutes ago
3 Reasons the Vanguard S&P 500 ETF Could Be Worth Holding for the Next 20 Years
MarketWatch
·
1 day ago
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy